文献速递甲状腺核医学核素与放射性配体治疗

[111In]In-CP04 作为新型胆囊收缩素-2 受体配体在进展性或转移性甲状腺髓样癌患者中的诊疗一体化潜力:GRAN-T-MTC I 期临床试验最终结果

[111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-11-05

GRAN-T-MTC 是一项 I 期多中心临床试验,纳入 16 例晚期或转移性甲状腺髓样癌(MTC)或降钙素倍增时间短的患者,评估 111In 标记的胆囊收缩素-2 受体(CCK2R)配体 [111In]In-CP04 在低肽质量(10 μg)与高肽质量(50 μg)下的安全性、生物分布与剂量学。结果显示未发生严重不良事件,200 MBq [111In]In-CP04 的有效剂量在 10 μg 与 50 μg 组分别为 7±3 mSv 与 7±1 mSv,联合输注 Gelofusine 使肾脏剂量降低 53%,闪烁显像在 13 例患者中阳性(检出率 81%),诊断性能优于常规影像。作者认为 [111In]In-CP04 是安全有效的放射性药物,在晚期 MTC 中具有诊疗一体化前景。

要点

  • 16 例患者中未发生严重不良事件,2 例出现一过性心动过速与潮红。
  • 200 MBq [111In]In-CP04 有效剂量:10 μg 组 7±3 mSv vs 50 μg 组 7±1 mSv。
  • Gelofusine 使肾脏剂量降低 53%,肾脏吸收剂量 0.044±0.019 mSv/MBq。

核心结论

  • 作者认为 [111In]In-CP04 是安全有效的放射性药物,在晚期 MTC 患者中具有诊疗一体化前景。

研究设计与样本

  • GRAN-T-MTC 为通过 I 期多中心临床试验开展的转化研究,纳入经证实的晚期/转移性 MTC 或降钙素倍增时间短的患者。
  • 采用两步设计,分别使用低肽质量 10 μg 与高肽质量 50 μg 进行安全性评估,较高肽质量被认为适合治疗应用。
  • 第二步以随机方式联合输注 Gelofusine,以评估其降低肾脏吸收剂量的可能性;并进行生物分布、剂量学与诊断性显像及术前、术中、术后临床与生化评估。

主要发现

  • 共纳入 16 例患者;两种肽质量给药后均未观察到严重不良事件,2 例患者出现一过性心动过速与潮红。
  • 随访中未观察到生化与临床状态变化。
  • 初步剂量学评估显示剂量最高的器官为膀胱,其次为肾脏与胃壁。
  • 200 MBq [111In]In-CP04 的有效剂量在 10 μg 与 50 μg CP04 时分别估计为 7±3 mSv 与 7±1 mSv。
  • Gelofusine 使肾脏剂量降低 53%,器官吸收剂量为 0.044±0.019 mSv/MBq;使用 [177Lu]Lu-CP04 时肾脏预计吸收剂量估计为 0.9±0.4 Gy/7.4 GBq。

关键数值与推荐

  • [111In]In-CP04 闪烁显像阳性 13 例,检出率 81%。
  • 200 MBq [111In]In-CP04 有效剂量:10 μg 组 7±3 mSv vs 50 μg 组 7±1 mSv。
  • Gelofusine 使肾脏剂量降低 53%,肾脏吸收剂量 0.044±0.019 mSv/MBq。
  • [177Lu]Lu-CP04 肾脏预计吸收剂量 0.9±0.4 Gy/7.4 GBq。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Medullary thyroid cancer (MTC) is a rare malignant tumour of the parafollicular C-cells with an unpredictable clinical course and currently suboptimal diagnostic and therapeutic options, in particular in advanced disease. Overexpression of cholecystokinin-2 receptors (CCK2R) represents a promising avenue to diagnostic imaging and targeted therapy, ideally through a theranostic approach. MATERIALS AND METHODS: A translational study (GRAN-T-MTC) conducted through a Phase I multicentre clinical trial of the indium-111 labelled CP04 ([111In]In-CP04), a CCK2R-seeking ligand was initiated with the goal of developing a theranostic compound. Patients with proven advanced/metastatic MTC or short calcitonin doubling time were enrolled. A two-step concept was developed through the use of low- and high-peptide mass (10 and 50 μg, respectively) for safety assessment, with the higher peptide mass considered appropriate for therapeutic application. Gelofusine was co-infused in a randomized fashion in the second step for the evaluation of potential reduction of the absorbed dose to the kidneys. Imaging for the purpose of biodistribution, dosimetry evaluation, and diagnostic assessment were performed as well as pre-, peri-, and postprocedural clinical and biochemical assessment. RESULTS: Sixteen patients were enrolled. No serious adverse events after application of the compound at both peptide amounts were witnessed; transient tachycardia and flushing were observed in two patients. No changes in biochemistry and clinical status were observed on follow-up. Preliminary dosimetry assessment revealed the highest dose to urinary bladder, followed by the kidneys and stomach wall. The effective dose for 200 MBq of [111In]In-CP04 was estimated at 7±3 mSv and 7±1 mSv for 10 μg and 50 μg CP04, respectively. Administration of Gelofusine reduced the dose to the kidneys by 53%, resulting in the organ absorbed dose of 0.044±0.019 mSv/MBq. Projected absorbed dose to the kidneys with the use of [177Lu]Lu-CP04 was estimated at 0.9±0.4 Gy/7.4 GBq. [111In]In-CP04 scintigraphy was positive in 13 patients (detection rate of 81%) with superior diagnostic performance over conventional imaging. CONCLUSION: In the present study, [111In]In-CP04 was shown to be a safe and effective radiopharmaceutical with promising theranostic characteristics for patients with advanced MTC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lezaic L, Erba PA, Decristoforo C, et al. [111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial. Eur J Nucl Med Mol Imaging. 2022. PMID: 36334104. doi:10.1007/s00259-022-05992-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。